Jane Street’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jane Street’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,200	Closed	-$155K	–	10218
2023 Q4	$155K	Sell	10,200 -13,500	-57%	-$197K	﹤0.01%	8380
2023 Q3	$475K	Sell	23,700 -1,700	-7%	-$43.1K	﹤0.01%	6372
2023 Q2	$717K	Buy	25,400 +9,000	+55%	+$216K	﹤0.01%	5758
2023 Q1	$282K	Buy	+16,400	New	+$332K	﹤0.01%	7298
2022 Q4	–	Sell	-19,700	Closed	-$427K	–	10300
2022 Q3	$427K	Buy	19,700 +9,600	+95%	+$263K	﹤0.01%	6975
2022 Q2	$284K	Sell	10,100 -5,900	-37%	-$156K	﹤0.01%	7696
2022 Q1	$738K	Buy	16,000 +9,400	+142%	+$507K	﹤0.01%	6748
2021 Q4	$555K	Buy	+6,600	New	+$511K	﹤0.01%	7063
2021 Q3	–	Sell	-33,000	Closed	-$1.76M	–	10878
2021 Q2	$1.76M	Buy	+33,000	New	+$1.77M	﹤0.01%	4581

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Jane Street's ZNTL Position: Q1 2026 in Review

Jane Street increased its Zentalis Pharmaceuticals (ZNTL) stake by 3.6% in Q1 2026, buying an estimated $44.3K and bringing the position to 490,339 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #6217.

Jane Street first reported a position in ZNTL in Q2 2020 and has held it in 19 quarters since. The position peaked at $1.96M in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Jane Street held 490,339 shares of Zentalis Pharmaceuticals worth $1.15M as of Q1 2026.
Jane Street bought 17,164 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $44.3K.
Zentalis Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #6217 holding.
Jane Street first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
Jane Street's Zentalis Pharmaceuticals position peaked at $1.96M in Q1 2024.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.